About this webinar

Recorded On: Wednesday, February 12, 2020

When interpreting a variant using the AMP/ASCO guidelines for somatic variant interpretation, clinicians must determine whether the variant can be considered a biomarker that affects clinical care by predicting sensitivity, resistance, or toxicity to a specific therapy. Such a determination requires the investigation of multiple evidence sources, including clinical trials, FDA approved therapies and peer-reviewed studies. Unfortunately, strong evidence linking specific genetic biomarkers to FDA-approved therapies only exists for a small number of cancers. Thus, most variants require an exploration of clinical practice guidelines, peer-reviewed literature, and large-scale cancer mutation databases to effectively assess the clinical significance of a given mutation.

This webcast explores this new incorporation of Drugs & Trials Annotations in VSClinical's AMP Workflow covering:

• Identification of relevant clinical evidence for drug sensitivity and resistance based on patient biomarkers and tumor type
• Review of clinical trial information including inclusion criteria, trial status, and contact information
• Management of citations associated with relevant, targeted therapies
• Evaluation of a biomarkers clinical evidence tier based on available evidence for drug sensitivity and resistance

You can read more about this webcast over on our blog! Or, you can view this from the user's perspective in the next webcast of our series here.